The Premier APAC Commercialization Platform for Western Medical Innovation
We architect rapid-revenue entry strategies and direct clinical deployment for FDA/EMA-approved advanced therapeutics and diagnostic hardware into the Chinese healthcare ecosystem
Strategic Advisory & APAC Market Access
Retained advisory for independent mid-cap biotechs mapping their China entry. We bypass standard NMPA delays via the Hainan Boao Lecheng "Urgent Clinical Need" mandate.
Direct Clinical Deployment
Acting as the exclusive Importer of Record. We deploy diagnostic hardware and advanced therapeutics directly into our Joint Venture network of 1,000+ top-tier Chinese hospitals.
Cross-Border M&A & Capital Partnerships
Facilitating light-asset acquisitions, IP licensing, and strategic capital partnerships for advanced medical technologies (Orphan Drugs, Advanced Oncology Therapeutics, Surgical Robotics, and Next-Gen Diagnostic Platforms).
The standard regulatory pathway for Western medical technology in China takes 5 years and millions in bridging studies. Santec eliminates this friction. By leveraging the Hainan Boao Lecheng International Medical Tourism Zone, we enable Western innovators to import their FDA/EMA-cleared assets immediately for cash-pay VIP patients. We secure your IP, generate day-one revenue, and capture the Real-World Data (RWD) mandated by the NMPA for national approval.
We do advise, operate, fund, and execute.